Latest data shows need to promote biosimilar and value added medicines

Biosimilar medicines are transforming treatment by enabling better access to biological medicines in Europe and around the world, as stated during the second day of the joint Medicines for Europe-IGBA conference in Lisbon, Portugal.

The IGBA (International Generic and Biosimilar Association) has commissioned new user-friendly material to acquaint and empower stakeholders with relevant information on the science and benefits of biosimilar medicines.

A new study on value added medicines highlights the necessary reforms in health technology assessment (HTA) decision frameworks in Europe to ensure market entrance of value added medicines to improve the treatment of chronic diseases in areas such as respiratory or mental health treatment. This innovative methodology will also enable new business models for value added antibiotics to address the growing threat of antimicrobial resistance.